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Eit ord 
 
Eit ord 
- ein stein 
i ei kald elv. 
Ein stein til – 
Eg lyt ha fleire steinar 
skal eg koma yver. 
 
 
 
 
One word 
 
One word 
- one stone 
in a cold stream. 
One more stone - 
I need more stones 
if I am to cross. 
 
    
 
 
Olav H. Hauge, Norwegian poet 
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Summary in English 
Background and objectives 
The prevalence of Parkinson’s disease (PD), today affecting about 2% of the 
population aged 65 years and older, is expected to double by the year 2030. 
The disorder causes significant patient and caregiver burden, particularly as the 
disease progresses and additional problems such as depression, fatigue, 
hallucinations and cognitive impairment occur. Until recently, there was little 
insight into the causes of PD. Over the last 11 years several genes causing 
familial parkinsonism have been linked and identified through positional cloning. 
The identification of the first of these genes, α-synuclein defined PD as a 
synucleinopathy. The identification of Leucine-rich repeat kinase 2 (LRRK2) 
gene mutations in clinically typical, late-onset PD highlighted the role of genetics 
in this disorder. The aim of this thesis was to identify further genetic causes of 
PD. We did this by fine-mapping a genetic locus that had been linked to late-
onset PD in the Icelandic population (PARK10) (Paper I), by conducting 
replication studies of reported associations to validate the findings (Paper II-III) 
and by investigating LRRK1 as a candidate gene for PD (Paper IV). 
 
Methods 
• DNA was collected from PD patients and healthy controls for inclusion 
in patient-control cohorts that we genotyped i) to assess the frequencies 
of genetic markers, and ii) to investigate whether marker alleles were 
associated with susceptibility to disease. 
 
• A clinical and genetic study of PD in central Norway was initiated 
several years ago by a movement disorder neurologist (Jan O. Aasly) at 
the Department of Neurology, St. Olav’s Hospital (Trondheim University 
Hospital). He has now colleted DNA samples from more than 600 PD 
patients and more than 500 controls (Papers I-IV). Additional 
Norwegian controls for Paper I were recruited from a study on dementia 
in central Norway (Trønderbrain) by another neurologist (Sigrid B. 
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Sando). In Papers I-III we also employed PD patient-control series from 
Ireland and the United States. 
 
• In Paper I, we genotyped single nucleotide polymorphisms (SNPs) 
across the PARK10 linkage peak in Norwegian and Irish samples. We 
then followed-up on SNPs showing evidence of association (P≤0.05) by 
genotyping them in additional samples. The follow-up stage also 
included SNPs that had been associated with PD risk in previous 
studies.  
 
• In Paper II, we genotyped SNPs in the ELAVL4 gene, based on a 
previous study that had nominated these SNPs to be associated with 
age at onset (AAO) of PD.  
 
• In Paper III, we followed-up on the top 11 ‘hits’ from the first genome 
wide association (GWA) study in PD. Additionally, we followed up on 
two PARK10 SNPs that showed evidence of association with 
susceptibility to PD in the GWA study. 
 
• In Paper IV, we investigated the role of genetic variability in the LRRK1 
gene in the Norwegian population. 
 
Results 
• We found that SNPs in the USP24 gene are associated with 
susceptibility to PD (Paper I). No other SNPs showed consistent 
evidence of association with PD or AAO in that study.  
 
• ELAVL4 markers were not associated with AAO or susceptibility to PD 
in the Norwegian or US patient-control series, but there was evidence 
for association with susceptibility to PD in the Irish series (Paper II).  
 
• We could not replicate any of the genetic loci nominated to influence PD 
by the first GWA-study in PD (Paper III). 
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• None of the LRRK1 variants investigated appear to be implicated in the 
etiology of PD in the Norwegian population (Paper IV). 
Conclusions 
• The evidence implicating USP24 in PD (Paper I) is in agreement with a 
previous smaller study. However, association does not imply a causal 
link and spurious associations may occur when simultaneously testing 
many hypotheses. Consequently, we highlight the need for replication 
of our findings. Furthermore, it is clear that the modest risk in terms of 
odds ratios (ORs) does not explain the PARK10 linkage peak. We 
observed ORs of 0.78-0.80 for the minor allele, corresponding to ORs 
of 1.20-1.22 for the major allele. 
 
• The lack of consistency for the association between ELAVL4 SNPs and 
PD in Paper II may have two reasons; i) the finding may represent a 
spurious association or ii) it may represent a population specific 
association. Independent replication for these markers is warranted to 
clarify the issue. 
 
• The work of others and our group (Paper III) indicates that all 13 SNPs 
identified by the first GWA-study in PD may be false positives. Future 
GWA-studies in PD may be successful if insights derived from this 
pioneer study are implemented in future study design.  
 
• The findings in Paper IV indicate that genetic variability in LRRK1 does 
not play a major role in the etiology of PD in Norway. However, a role 
for this gene in PD patients from other populations cannot be excluded. 
 
 
 11 
Summary in Norwegian 
Bakgrunn og målsetningar 
Prevalensen av Parkinson sjukdom, som i dag råkar omlag 2% av dei som er 65 
år gamle eller eldre, er venta å doblast til år 2030. Denne sjukdomen belastar 
både pasientane og dei pårørande, særleg er dette tilfellet i framskridne stadier 
av sjukdomsutviklinga der pasientane ofte opplever problem med depresjon, 
auka trøyttleik, hallusinasjonar og reduserte kognitive evner. Inntil nyleg hadde 
ein liten kunnskap om årsakene til Parkinson sjukdom. Over dei siste 11 åra har 
fleire sjukdomsutløysande gener vorte identifisert ved bruk av genetiske 
koplingsstudiar og posisjonell kloning. Oppdaginga av det første av desse 
genene, α-synuclein, førde til at Parkinson sjukdom vart klassifiert som ein 
synucleinopati. Oppdaginga av at mutasjonar i Leucine-rich repeat kinase 2 
(LRRK2) genet fører til klinisk typisk Parkinson sjukdom med sein 
sjukdomsdebut, stadfesta at genetikk speler ei rolle ved denne sjukdomen. 
Målet med denne avhandlinga var å identifisere fleire genetiske årsaker til 
Parkinson sjukdom. Framgangsmåten me nytta var å finkartleggje eit genetisk 
lokus som hadde vorte kopla til Parkinson sjukdom i ein populasjon frå Island 
(PARK10) i artikkel I. Vidare gjennomførde me replikasjonsstudiar for å validere 
funn frå tidlegare studiar (Artikklane II-III). I Artikkel IV undersøkte me LRRK1 
genet, avdi dette genet var ein klar kandidat som kunne vere involvert i 
prosessen som fører til Parkinson sjukdom. 
 
Metodar 
• DNA vart innhenta frå pasientar med Parkinson sjukdom og friske 
kontrollindivid. Desse prøvane vart nytta i pasient-kontroll studiar for å 
undersøkje om frekvensen av allelar var ulik mellom gruppene, dvs. om 
desse allelane var assosierte med sjukdomen. 
 
• Ein kliniskgenetisk studie i Midt Noreg vart starta for fleire år sidan av 
ein nevrolog (Jan O. Aasly) ved St. Olav’s Hospital. Han har no samla 
prøvar frå meir enn 600 pasientar og over 500 kontroll individ 
(Artikklane I-IV). I tillegg nytta me kontrollar samla gjennom ein studie 
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av demens i Trøndelag i artikkel I. Desse kontrollane var rekrutterte av 
ein annan nevrolog (Sigrid B. Sando). I artikklane I-III nytta me også 
pasient-kontroll seriar frå Irland og USA. 
 
 
• I artikkel I gjennomførde me genetiske analysar av genetiske markørar 
(einskildnukleotidpolymorfismar: SNPs) spreidde over PARK10 locuset i 
norske og irske prøvar. Deretter gjennomførde me oppfølgjingsstudiar 
for markørar som synte assosiasjon (P≤0.05) ved å analysera desse i 
eit utvida materiale. Dette oppfølgjingstrinnet inkluderte også markørar 
som hadde synt assosiasjon i andre studiar. 
 
• I artikkel II analyserte me markørar i ELAVL4 genet, avdi desse hadde 
vorte assosiert med alder for sjukdomsdebut for Parkinson sjukdom i 
ein tidlegare studie. 
 
 
• I artikkel III gjorde me ein replikasjonsstudie av funna frå den første 
genomomfattande assosiasjonsstudien gjennomførd i Parkinson 
sjukdom. I tillegg analyserte me to PARK10 markørar som synte 
assosiasjon med risiko for Parkinson sjukdom i den nemde studien. 
 
 
• I artikkel IV undersøkte me om genetiske variantar i LRRK1 genet var 
risikofaktorar for Parkinson sjukdom i den norske befolkinga. 
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Resultat 
• Me fann at genetiske markørar i USP24 genet er assosierte med 
predisposisjon for Parkinson sjukdom (artikkel I). Ingen andre 
gener/markørar synte teikn til ein slik assosiasjon. 
 
• Markørar i ELAVL4 genet er ikkje assosierte med sjukdomsdebutalder 
eller risiko for Parkinson sjukdom i den norske eller amerikanske serien, 
derimot var det ein assosiasjon med sjukdomsrisiko i den irske serien 
(artikkel II). 
 
• Me kunne ikkje reprodusera noko av funna frå den første 
genomomfattande assosiasjonsstudien i Parkinson sjukdom (Artikkel 
III). 
 
• Dei genetiske variantane som vart undersøkte i artikkel IV var ikkje 
assosiert med risiko for Parkinson sjukdom i den norske populasjonen. 
 
 
Konklusjonar 
• Assosiasjonen mellom genetiske markørar i USP24 genet og 
predisposisjon for Parkinson sjukdom stemmer overeins med ein 
tidlegare, men mindre studie (artikkel I). Det er viktig å understreka at 
assosiasjon ikkje er det same som årsakssamanheng og tilfeldige 
assosiasjonar kan opptre når mange hypoteser vert undersøkte 
samstundes. Av denne grunn understrekar me at det er naudsynt å 
reprodusera resultata våre. Vidare er det klart at våre resultat ikkje 
forklarar PARK10-koplinga, avdi den observerte effektstorleiken er for 
liten (odds ratios [ORs]) 0.78-0.80 for den lågfrekvente allelen, noko 
som korresponderer til ORs 1.20-1.22 for den høgfrekvente allelen. 
 
• Assosiasjonen mellom ELAVL4 markørar og Parkinson sjukdom i den 
Irske serien stemmer ikkje overeins med funna i den norske og 
amerikanske serien. Denne observasjonen kan ha to ulike forklaringar: 
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i) Assosiasjonen kan vere eit tilfeldig funn eller ii) assosiasjonen kan 
representere populasjons spesifikke risikofaktorar. Uavhengige 
reproduksjonsstudiar trengst for å avklare dette. 
 
• Vår forsking og studiar frå andre forskingsgrupper syner at dei 13 
genetiske markørane som vart identifisert i den første 
genomomfattande assosiasjonsstudien i Parkinson sjukdom truleg var 
falsk positive funn. Denne typen assosiasjonsstudiar kan framleis ha 
stort potensiale til å finna årsaker til denne sjukdomen dersom ein 
byggjer vidare på erfaringane frå denne tidlege studien. 
 
• Funna som er presanterte i artikkel IV tyder på at genetisk variabilitet i 
LRRK1 genet ikkje spelar ei stor rolle i molekulærbiologien ved 
Parkinson sjukdom. Me kan ikkje utelukka at dette genet spelar ei rolle i 
andre populasjonar. 
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Abbreviations and definitions 
AAO Age at onset 
AD Alzheimer’s disease 
ALS Amyotrophic lateral sclerosis 
ATP13A2 ATPase type 13A2 
CI Confidence interval 
DLB Dementia with Lewy bodies 
DNA Deoxyribonucleic acid (containing the genetic code) 
EOPD Early-onset Parkinson’s disease 
Genotype The particular set of alleles that an individual has at a given 
 region of the genome. 
GIGYF2 Grb 10-Interacting GYF Protein 2 
GWA-study Genome wide association study  
Haplotype A particular combination of alleles that are closely linked 
 on a chromosome. 
KRS Kufor Rakeb Syndrome 
LBD Lewy body disease 
LD Linkage disequilibrium 
LOD-score Logarithm of odds score 
LOPD Late-onset Parkinson’s disease 
LRRK2 Leucine-rich repeat kinase 2 (gene); Lrrk2 (protein)  
MAF Minor allele frequency 
MAPT Microtubule-associated protein tau 
MPTP N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MSA Multiple system atrophy 
Mutation  An alteration in a genome compared to some reference state 
with frequency <1%, but not necessarily pathogenic.  
OMI/HTRA OMI/HTRA serine peptidase 2 
OMIM Online Mendelian Inheritance in Man  
 (see; http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim) 
ORs Odds ratios 
PD Parkinson’s disease 
PDD Parkinson’s disease dementia 
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PET Positron emission tomography 
PGRN Progranulin 
Phenotype The observable properties and characteristics of an 
 individual or a locus 
PINK1 PTEN-induced kinase 1 
PRKN Parkin 
RLS Restless legs syndrome 
Polymorphism A region on the genome that varies between individual  
  members of a population with frequency >1%. 
PSP  Progressive supranuclear palsy 
RBD  REM sleep behavior disorder 
SNCA  α-synuclein 
SNP  Single nucleotide polymorphism 
SPECT  Single photon emission computer tomography 
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1. Introduction 
1.1 Historical background 
The clinical syndrome we refer to as Parkinson’s disease (PD [OMIM #168600]) 
was first described in 1817 by James Parkinson (1755-1824) in his classical 
publication “An essay on the shaking palsy” (Paralysis Agitans) (1). In his work 
Parkinson described the motor signs that define this disorder: 
 
Shaking Palsy (Paralysis Agitans): 
“Involuntary tremulous motion, with lessened 
muscular power, in parts not in action and even 
when supported; with a propensity to bend the 
trunk forwards, and to pass from a walking to a 
running pace: the senses and intellects being 
uninjured.” 
 
Interestingly, Parkinson also described nonmotor 
features of this disorder, e.g. his mentioning of 
symptoms that would now be attributed to REM 
sleep behavior disorder (RBD); “the sleep 
becomes much disturbed. The tremulous motion 
of the limbs occurs during sleep, and augment 
until they awaken the patient, and frequently with much agitation and alarm.”  
Finally, in the end stage of the disease Parkinson’s description includes fatigue 
and hallucinations: “..at the last, constant sleepiness, with slight delirium, and 
other marks of extreme exhaustion, announce the wished-for release.” 
Figure 1. James Parkinson’s 
original publication from 1817 
 
It was the work of the great French neurologist Jean-Martin Charcot (1825 – 
1893) who brought general attention to Parkinson’s description. Charcot further 
defined the syndrome by adding rigidity to the motor signs, and he coined the 
term maladie de Parkinson. 
 
For a long time PD remained a devastating disorder with no effective treatment. 
In their 1957 publication, Carlsson et al. first demonstrated that levodopa, a 
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dopamine precursor that crosses the blood-brain barrier, reverses reserpine-
induced parkinsonism in mice and rabbits (2) and later that dopamine is a 
neurotransmitter present in the brain (3). This was followed by the work of 
Ehringer and Hornykiewicz demonstrating striatal dopamine deficiency in brains 
of PD patients (4). Birkmayer and Hornykiewicz built on this work by 
demonstrating for the first time that levodopa improves parkinsonism in humans 
(5). After some initial controversy, Cotzias and colleagues established the 
efficacy of dopamine replacement therapy in PD when they reported dramatic 
improvement in PD patients with oral administration of levodopa in increasing 
amounts over long periods (6).  
 
The levodopa revolution is to date the basis of motor symptom treatment in PD. 
Although a wide range of compounds have been developed since 1960, 
levodopa remains the single most effective symptomatic treatment for PD. 
Surgical treatment for PD has been available for decades, and was significantly 
improved by the introduction of continuous deep brain stimulation (DBS) in the 
1990’s. DBS of the subthalamic nucleus (STN) is now established as a well-
documented treatment for carefully selected, particularly young patients, with 
fluctuating motor symptoms and dyskinesias (7-9).  
 
Over the last decades it has become increasingly clear, however, that PD 
patients suffer from symptoms that go beyond the classical motor features that 
define the disease. These nonmotor symptoms result in disability, diminish 
quality of life for patients and contribute substantially to caregiver burden (10). 
Most nonmotor symptoms do not respond to levodopa treatment (11-13). This 
insight has increasingly highlighted PD as a multisystem brain disorder and that 
novel treatment that reaches beyond the nigrostriatal system is needed (14, 15). 
 
Genetics has proven effective in identifying key proteins involved in 
neurodegeneration (16). The identification of these proteins opens new avenues 
of research and will advance our insight into the molecular mechanisms that 
underlie PD. Furthermore, unaffected mutation carriers may be ideal candidates 
to benefit from future neuroprotective treatments. The goal of the work 
presented in this thesis was to identify further genes implicated in PD, and thus 
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contribute to novel insight that may result in improved future therapies aimed at 
halting and preventing disease progression. 
 
1.2 Definitions 
Parkinsonism 
 
Table 1.  Six cardinal clinical features of parkinsonism (from ref. 14) 
• Tremor at rest  
• Bradykinesia  
• Rigidity  
• Loss of postural reflexes  
• Flexed posture of neck, trunk, and limbs  
• Freezing phenomenon 
 
Fahn defined the term parkinsonism as any combination of six specific motor 
features: tremor at rest, bradykinesia, rigidity, loss of postural  
reflexes, flexed posture and the freezing phenomenon (where the feet are 
transiently “glued to the ground”), see table 1 (17). Two of the six motor features 
should be present, and at least one of them should be tremor at rest or 
bradykinesia, before a diagnosis of parkinsonism is made (17). There are 
numerous causes of parkinsonism, see table 3. 
 
 
Parkinson’s disease 
PD is the most common cause of parkinsonism. The diagnosis of PD is based 
on the clinical identification of some combination of the four cardinal motor signs 
(tremor at rest, bradykinesia, rigidity and postural instability), with most criteria 
requiring at least the presence of tremor at rest or bradykinesia. Additional 
features include; asymmetry at disease onset and favorable response to 
levodopa treatment. There should be an absence of atypical symptoms e.g. 
early falls, severe autonomic dysfunction, early dementia or supranuclear gaze 
palsy. In addition, imaging and clinical examination should exclude other causes 
of parkinsonism (Table 3). 
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No biomarker is established for the routine diagnosis of PD, and PD remains a 
clinical diagnosis. Routine blood tests, structural imaging of the central nervous 
system and other paraclinical tests are mainly used to distinguish other forms of 
parkinsonism. Functional imaging assessing neurotransmitter activity in the 
nigrostriatal dopaminergic system, such as SPECT and PET, can be helpful to 
reveal dopaminergic deficiency and to differentiate PD from other causes of 
parkinsonism (18). 
 
The clinical signs of parkinsonism may be subtle at disease onset and this can 
lead to misdiagnosis (19). Application of strict diagnostic criteria has been 
shown to increase the diagnostic accuracy (20). Furthermore, following the 
patients longitudinally is important to achieve high diagnostic accuracy (21). 
Several groups have therefore proposed diagnostic criteria for a diagnosis of 
PD, to reliably distinguish PD from other forms of parkinsonism. The criteria 
proposed by Gelb and colleagues were used for the diagnosis of PD in papers I-
IV (22). Gelb et al. differentiated three levels of diagnostic confidence; definite, 
probable and possible. The diagnoses of possible and probable PD are based 
on clinical criteria alone, whereas neuropathological confirmation is required for 
the diagnosis of definite PD (Table 2) (22). 
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Table 2. Diagnostic criteria for PD (from Gelb et al., ref. 19) 
Grouping of clinical features according to diagnostic utility 
Group A features: characteristic of PD 
  Resting tremor 
   Bradykinesia 
   Rigidity 
   Asymmetric onset 
Group B features: suggestive of alternative diagnoses 
   Features unusual early in the clinical course 
     - Prominent postural instability 
     - Freezing phenomena 
     - Hallucinations 
     - Dementia preceding motor symptoms or in the first year 
     - Supranuclear gaze palsy or slowing of vertical saccades 
     - Severe, symptomatic dysautonomia 
     - Documentation of a condition known to produce parkinsonism plausibly connected to the  
       symptoms 
 
Proposed diagnostic criteria for Parkinson’s disease  
Criteria for POSSIBLE diagnosis of PD 
   - At least 2 of 4 features in Group A, at least one of these is tremor or bradykinesia 
   - None of the features in Group B (or symptoms for less than 3 years) 
   - Response to dopaminergic treatment upon adequate trial 
Criteria for PROBABLE diagnosis of PD 
   - At least 3 of 4 features in Group A 
   - None of the features in Group B 
   - Response to dopaminergic treatment 
Criteria for DEFINITE diagnosis of PD 
   - All criteria for POSSIBLE PD are met 
   - Histopathological confirmation 
 
Familial and sporadic PD 
In this thesis, the term PD describes any patient fulfilling diagnostic criteria (22), 
and a family history of parkinsonism is not an exclusion criterion. In the 
literature, patients with a clinical syndrome indistinguishable from typical PD 
caused by known genetic mutations have been referred to using the terms PD 
and parkinsonism. It could be argued that patients affected by parkinsonism 
with a known etiology should not be referred to as having PD, and that this term 
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should be reserved for idiopathic cases. However, in many cases these patients 
fulfill all proposed diagnostic criteria (23, 24). Patients with an unknown cause of 
PD are referred to as having idiopathic PD. 
 
Sporadic PD is in this thesis defined as PD in a patient without any known first 
or second degree relative affected with parkinsonism or PD. Familial PD is 
defined as PD in a patient with at least one first or second degree relative with 
parkinsonism or PD. 
 
Autosomal dominant and recessive PD 
Autosomal dominant inheritance refers to genetic conditions that occur when 
mutations are present in one allele of a given gene i.e. one allele is dominant to 
the wild-type (standard) allele. If two or more members from the same family are 
affected by PD in at least two consecutive generations we considered the 
genetic transmission to be consistent with an autosomal dominant pattern of 
inheritance. Autosomal recessive inheritance refers to genetic conditions that 
occur only when mutations are present in both alleles of a given gene, i.e the 
allele is recessive to the wild-type (standard) allele. 
 
Early-onset Parkinson’s disease (EOPD) 
In this thesis a patient affected by parkinsonism at 50 years of age or earlier is 
considered to have early-onset Parkinson’s disease (EOPD). 
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Table 3. Classification of the parkinsonian states 
        Synucleinopathies  
        Lewy body disorders 
• Parkinson’s disease 
• Dementia with Lewy Bodies 
        Glial inclusion body disorders 
• Multiple system atrophy 
       Other synucleinopathies 
• Pantothenate kinase associated neurodegeneration 
• Pallidonigroluysian atrophy 
 
Tauopathies 
• Progressive supranuclear palsy 
• Corticobasal degeneration 
• FTDP-17(MAPT) 
• Pick’s disease 
• Alzheimer’s disease 
• Postencephalitic parkinsonism 
• Parkinsonism-dementia complex of Guam 
 
TDP-43proteinopathies 
• FTDP-17(PGRN) 
• Parkinsonism with alveolar hypoventilation and mental depression (Perry disease) 
 
Other neurodegenerative disorders (including trinucleotide repeat disorders) 
• SCA2 
• SCA3 
• Dentorubral-pallidoluysian atrophy 
• X-linked dystonia-parkinsonism (Lubag) 
• Levodopa responsive dystonia with parkinsonism (DYT5) 
• Fragile X tremor/ataxia syndrome (FXTAS) 
Secondary parkinsonism  
Drugs (antipsychotic medications, calcium channel blockers and others) 
Toxins: manganese, carbon monoxide, pesticides, MPTP, cyanide  
Vascular  
Brain tumors  
Head trauma  
Normal-pressure hydrocephalus  
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Linkage disequilibrium (LD) 
Linkage disequilibrium describes a situation in which some combinations of 
alleles or genetic markers occur together more frequently in a population than 
would be expected from a random formation of haplotypes from alleles based 
on their frequencies. Non-random associations between polymorphisms at 
different loci are measured by the degree of linkage disequilibrium (LD). If a 
genetic marker is in LD with a disease susceptibility locus, it would be expected 
that genotype and allele frequencies at the marker loci will differ between 
patients and control individuals. Investigations of such differences are known as 
association studies. 
 
Haplotype 
The combination of alleles found at neighboring loci on a single chromosome. 
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1.3 Epidemiology 
After Alzheimer’s disease (AD), PD is the most common neurodegenerative  
disorder affecting about 2% of the population aged 65 years and older (25). The 
prevalence of PD increases with age, which is the strongest risk factor for 
disease development. The mean age at disease onset is aproximately 60 years. 
PD is somewhat more likely to affect men than women (26). The age-adjusted 
prevalence rate in the county of Rogaland in Western Norway was found to be 
102.4 per 100,000 (26). Interestingly, using similar methodology Wermuth et al. 
found the age-adjusted prevalence in the nearby Faroe Islands to be twice as 
high (218.0 per 100,000) (27). This suggests that a genetic mutation or an 
environmental risk factor may be particularly common in specific populations. It 
is clear from the identification of the Lrrk2 p.G2019S substitution that the 
frequency of a specific genetic cause may vary dramatically between different 
populations (24). The importance of PD as a public health issue was further 
highlighted by a recent report projecting that the number of affected PD patients 
in the five most populous nations will double to between 8.7 and 9.3 million by 
2030 (28). 
 
1.4 Pathology of Parkinson’s disease 
Meynert for the first time implicated the basal ganglia in disorders of abnormal 
movements in 1871 (29). In 1895 Brissaud suggested the substantia nigra to be 
affected in PD (30). Brissaud based this on a report by Blocq and Marinesco of 
a tuberculoma in the substantia nigra associated with hemiparkinsonian tremor 
(31). The authors were careful to point out that the pyramidal tract and the 
brachium conjunctivum above and below the level of the lesion were not 
affected (17). Tretiakoff confirmed the importance of the substantia nigra in nine 
cases of PD, one case of hemiparkinsonism with a contralateral lesion in the 
substantia nigra and three cases of postencephalitic parkinsonism (32). The 
substantia nigra got its name because of the high content of neuromelanin. The 
pathological findings consisted of depigmentation, neural cell loss and gliosis. 
Tretiakoff also confirmed a finding originally described by Lewy in 1914 (33); 
cytoplasmatic inclusions in PD. These inclusions are now widely recognized as 
the pathological hallmark of PD and referred to as Lewy bodies (LBs). Since the 
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identification of α-synuclein gene mutations as a cause of familial parkinsonism  
(34), it has become clear that LBs contain substantial amounts of α-synuclein 
(35). The pathological diagnosis is Lewy body disease (LBD) which comprises 
the clinical diagnoses PD and PD with dementia (PDD), as well as dementia 
with Lewy bodies (DLB). Immunohistochemical staining for α-synuclein is now 
recommended for the pathological evaluation of LBD (36). 
 
Macroscopically, the PD brain is unremarkable or may display cortical atrophy 
and enlargement of the ventricles. The midbrain sections often show pallor of 
the substantia nigra and locus ceruleus (37). Notably, the striatum and globus 
pallidus appear normal. The microscopical findings feature LBs and Lewy 
neurites (LNs) that are associated with variable neuron loss in the brainstem, 
midbrain and other subcortical nuclei, in particular the substantia nigra and the 
locus ceruleus. There is severe depletion of melanized neurons (>50%) in the 
whole substantia nigra (37). Subregionally, nigral neuronal cell loss has been 
observed to be greatest in the ventrolateral part (94%) followed by the 
ventromedial part (70%), the dorsolateral part (65%), the dorsomedial part 
(58%) and pars lateralis part (57%) from control values, respectively (38). 
 
Incidental LBs are found in increasing amounts in the brains of unaffected 
individuals as they get older. It has also become clear that as many as 60% of 
AD cases may have some degree of LB pathology, mainly in the amygdala. 
Recent recommendations for diagnosing LBD comprise a semiquantitative 
grading of LB pathology rather than just the presence of LBs and LNs. The 
concurrent existence of AD pathology should also be taken into account (36). 
The current LBD scheme also includes an evaluation of the regional 
involvement of the LB and LN pathology; i.e. brainstem, limbic and diffuse 
cortical types. 
 
The identification of clinically typical, late-onset levodopa responsive PD caused 
by mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene has made it 
clear, however, that the clinical syndrome we refer to as PD may also be 
present in the absence of LBD (24, 39).  
 
 27 
1.5 Heritability of Parkinson’s disease 
Two students of Charcot at the Hôpital de la Salpêtrière in Paris were probably 
the first to highlight PD as a hereditary trait. In 1880 and 1883 Leroux and 
Lhirondel, respectively published their theses on PD (40, 41). They both 
reported that PD was hereditary and Leroux went so far as to state that “a true 
cause of paralysis agitans, and maybe the only true cause, is heredity”. This 
was followed by several reports, mainly from Europe, describing familial cases 
of PD (42-44).  
 
The first genetic-statistical analysis of PD was carried out in Sweden by Mjönes 
in the 1940’s (43). His study included 194 probands and their families, 
personally examining many probands and families. In addition he selected 
probands without regard to family history, and carefully recorded the family 
pedigrees.  
 
 
1.6 Environmental risk factors for Parkinson’s disease 
Until recently idiopathic PD was considered to be caused mainly by 
environmental factors (45). In 1983 Langston and colleagues identified 
parkinsonism in ‘the frozen addicts’ (abusers who injected themselves with self- 
synthesized drugs and subsequently developed parkinsonism) to be caused by 
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (46). This toxin was found 
to selectively damage cells in the substantia nigra by inhibition of mitochondrial 
complex I (47). Since then, rural living, well-water drinking, pesticides, certain 
metals and professional exposure to such toxins have been implicated in 
nigrostriatal degeneration and parkinsonism. However, there is no conclusive 
evidence proving that any environmental toxin causes PD (48). Smoking has 
been inversely associated with susceptibility to PD, but smoking does not 
appear to have any effect on disease progression (49). 
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1.7 Genetics of familial Parkinson’s disease 
Table 4. Genes and loci involved in PD 
Gene Locus Mode Mutations AAO Clinical features 
SNCA 
 
 
 
 
PARK1/4 
(4q21) 
AD p.A30P, 
p.E46K and 
p.A53T 
substitutions; 
genomic 
CNVs 
Onset earlier in 
triplications 
(24–48 years) 
than in 
duplications 
(38–65 years)  
Progressive, levodopa 
responsive 
parkinsonism with 
autonomic dysfunction 
and dementia. 
Parkin PARK2 
(6q25.2-
27) 
AR Homozygous/ 
compound 
heterozygous 
missense 
(>57) and 
exonic CNVs 
<45 years 
 (range 16–72  
years) 
Parkinsonism with slow 
progression, responsive 
to low doses of 
levodopa, with early 
dyskinesias, diurnal 
fluctuation and sleep 
benefit 
Unknown PARK3 
(2p13) 
AD N/A N/A Typical parkinsonism 
UCH-L1? PARK5 
(4p14) 
AD p.I93M 
substitution 
55–58 years Typical parkinsonism 
PINK1 PARK6 
(1p35-36)  
AR Missense 
and exonic 
CNVs 
20–40 years Slow progression, 
responsive to low 
doses of levodopa, 
some with dyskinesias 
DJ-1 PARK7 
(1p36) 
AR Homozygous 
missense 
and deletion 
(delEx1–5) 
mutations, 
compound 
heterozygote
s 
20–40 years EOPD; Slow 
progression, levodopa 
responsive. 
LRRK2 PARK8 
(12q12) 
AD Substitutions; 
p.R1441C/G, 
p.Y1699C, 
p.G2019S 
and p.I2020T  
50–70 years  
(range 32–79) 
Predominantly 
levodopa responsive 
LOPD.  
ATP13A2 
? 
PARK9 
(1p36) 
AR Homozygous/ 
compound 
heterozygous  
CNVs 
12–18 years Juvenile levodopa 
responsive 
parkinsonism; 
pyramidal 
degeneration,  gaze 
palsy, spasticity and 
dementia 
Unknown PARK10 
(1p32)  
N/A N/A N/A Typical parkinsonism 
GIGYF2 ? PARK11 
(2q36-37) 
AD? Missense 
mutations? 
N/A Typical parkinsonism 
Unknown PARK12 
(Xq21-
25) 
X-
linked 
N/A N/A  
OMI/ 
HTRA2 ? 
PARK13 
(2p12) 
AD p.G399S 49-77 years Typical parkinsonism 
AAO; Age at onset. AD, autosomal dominant; AR, autosomal recessive; CNVs; copy number 
variants, N/A; not available, ?; role in PD is unresolved. 
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Over the last 11 years genetic linkage studies and subsequent positional 
cloning have been tremendously successful in identifying causes of familial 
parkinsonism (Table 4). The first gene identified α-synuclein (SNCA) defined 
PD as a synucleinopathy (34, 35). In 2004 another breakthrough was reached 
when mutations in Leucine-rich repeat kinase 2 (LRRK2) were identified in 
families with clinically typical, late-onset Parkinson’s disease (LOPD) (39, 50). 
Furthermore, the Lrrk2 p.G2019S substitution was identified as a common 
cause of LOPD (24). 
 
α-synuclein (PARK1/4 [OMIM *163890])  
In 1996 a genome wide linkage analysis in an Italian family (known as the 
Contursi kindred) with autosomal dominant parkinsonism mapped a locus on 
chromosome 4q21 (PARK1) (51). This lead to the identification of a missense 
mutation (c.209G>A) in the SNCA gene as the cause of disease in the Contursi 
kindred and three further families (34). This mutation leads to a p.A53T amino 
acid substitution in the α-synuclein protein. Subsequently, two further missense 
mutations, c.88C>G (p.A30P) and  c.188G>A (p.E46K) were identified in 
German and Spanish families respectively (52, 53). It is clear, however that 
these missense mutations are rare. 
 
The three missense mutations in the SNCA gene alter the function of the protein 
and are believed to promote aggregation of the protein (54, 55). This is of 
particular interest as the aggregated α-synuclein is the major component of 
Lewy bodies (LBs) and Lewy neurites (LNs) (35). These are the hallmark 
neuropathological findings in sporadic PD. 
 
Further insight was gained from the identification of genomic multiplications of 
the SNCA gene locus as a cause of parkinsonism (56). SNCA triplictions have 
been found in an American and a Swedish-American kindred (14, 56). 
Interestingly, the Swedish-American family has now been shown to be the 
largest family (the Lister family) described by Henry Mjönes in his 1949 thesis 
on familial aggregation of PD in Sweden (43, 57). It is also clear that the 
phenotype that segregates with disease even within the same family is 
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dependent on the SNCA gene dosage, with an earlier AAO and more severe 
autonomic dysfunction in triplication carriers compared to duplication carriers 
(57, 58). SNCA duplications have been identified in two French families (59, 
60), the Lister family (57) and two Japanese families (61). Recently, SNCA 
duplications were identified in three apparently sporadic PD patients from Korea 
(62). SNCA multiplications are associated with increased α-synuclein mRNA 
and protein in brain tissue (14, 63). Screening large series of PD patients has 
demonstrated that SNCA multiplications are a rare cause of PD, though more 
common than SNCA missense mutations. However, their identification provides 
important insights by demonstrating that there is a link between α-synuclein 
expression and disease severity (14, 64, 65).  
 
Importantly, genetic variability within the SNCA gene locus has consistently 
been associated with susceptibility to sporadic PD with odds ratios (ORs) of 
about 1.5 (66-71). The variants are located from the promoter to the 3’ end of 
the SNCA gene and are in LD. The functional variant(s) underlying this 
association have yet to be discovered. It is tempting to hypothesize that such 
variants may cause PD through a modest increase in α-synuclein expression. 
Thus far, however there are no data proving this (72). 
 
Parkin (PRKN) (PARK2 [OMIM *602544])   
AAO before age 45 years is a typical feature in autosomal recessive forms of 
familial EOPD; see table 4 (73, 74). A locus for EOPD was mapped to 
chromosome 6q25.2-27 in 1997 and the causative gene was identified as parkin 
(PRKN) (75, 76). The first parkin mutations were large homozygous deletions of 
one and five exons, respectively (76). Since then numerous mutations have 
been identified, including deletions, duplications and triplications of exons, 
frameshift mutations and point mutations (missense, nonsense and splice-site 
mutations) (77). Mutations have been found in each domain of parkin. Parkin is 
reported to act as an E3-ubiquitin ligase and play a functional role in 
proteosomal degradation and receptor trafficking (78).  Parkin mutations usually 
occur either as homozygous or compound heterozygous mutations (with 
different mutations in both alleles). A role for heterozygous parkin mutations has 
been debated. In a large European study of patients with an age of onset <45 
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years (or with an affected sibling showing such an early onset), parkin mutations 
were identified in up to 50% of familial cases, and in 18% of sporadic disease 
(79-81). However, affected individuals with parkinsonism having AAO <45 years 
account for only 1% of idiopathic PD patients. The role of heterozygous parkin 
mutations and other parkin variants in idiopathic PD disease is not clear (82-84). 
 
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1)  
(PARK5 [OMIM +191342]) 
In 1998, Leroy et al. identified a missense mutation in the UCH-L1 gene 
c.277C>G; p.I93M) in a German sib-pair with PD (85). It is clear that the 
findings of Leroy et al. have never been replicated and thus the association is 
uncertain (86). Lincoln et al. sequenced the entire UCH-L1 coding region in 11 
families with autosomal dominant inheritance and only identified one missense 
polymorphism p.S18Y (87). This polymorphism was found in approximately 20% 
of chromosomes in a Caucasian population, suggesting that it is unlikely to be 
pathogenic. Association between the p.S18Y variant and susceptibility to PD 
has been reported (88-91). Recently, however two large studies did not find 
evidence supporting the role of p.S18Y as a susceptibility factor for PD (86, 92).  
 
PTEN-induced kinase 1 (PINK1) (PARK6 [OMIM*608309]) 
Valente et al. linked autosomal recessive EOPD in a large Sicilian family (known 
as the Marsala kindred) to PARK6, a 12.5-cM region of 1p36-p35 (93). 
Subsequently, they  identified mutations in PTEN-induced putative kinase 1 
(PINK1) as the cause of disease (94). Several mutations in PINK1 have since 
been found in different populations. The first pathogenic substitutions identified 
were two G>A transitions in nucleotide 926 (p.G309D) and 1311 (p.W437X), in 
families from Spain and Italy (94). Mutations were also found in two early-onset 
sporadic patients suggesting this gene may play a role in the more frequent 
sporadic form of PD, but this only rarely seems to be the case (95).  A 
heterozygous deletion of the entire PINK1 gene and a splice-site mutation on 
the remaining copy were recently described (96). The role of heterozygous 
PINK1 mutations in PD has yet to be fully resolved (97, 98). Common genetic 
variants within PINK1 do not appear to influence the risk of sporadic PD (99). 
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Oncogene DJ-1 (PARK7 [OMIM *602533]) 
PARK7 was first mapped to chromosome 1p36 in two families from a genetically 
isolated community in the Netherlands (100). This finding was later replicated in 
two independent families (101). In 2004, mutations in DJ-1 were found to cause 
early-onset autosomal recessive PD in these families (102). Both homozygous 
deletions and missense mutations in DJ-1 have been identified. However, these 
mutations only account for a small number of EOPD. Maraganore et al. 
investigated four DJ-1 haplotype tagging SNPs in PD. None of the four SNPs 
was associated with PD overall, but two SNPs were associated with PD in 
women (P=0.03 and P=0.002) (103). 
 
Leucine-rich repeat kinase 2 (LRRK2) (PARK8 [OMIM *609007]) 
The PARK8 locus on chromosome 12q12 was linked to clinically typical, LOPD 
in a large Japanese family known as the Sagamihara kindred (104). The mode 
of transmission was autosomal dominant with reduced penetrance. The PARK8 
linkage was confirmed in several PD families of European descent (105). 
Positional cloning of Leucine-rich repeat kinase 2 (LRRK2) as the disease 
causing gene was reported in 2004 by two groups (39, 50). This represented a 
major breakthrough in PD genetics as the identification of LRRK2 mutations in 
levodopa responsive LOPD made it clear that genetics definitively plays a role 
in this disorder. Shortly thereafter, a 6055G>A mutation (p.G2019S) in the 
kinase domain was identified as a relatively common cause of PD (106). 
Interestingly, most carriers of this mutation can be linked back to a common 
founder that lived several thousand years ago (24, 106, 107). The frequency of 
Lrrk2 p.G2019S parkinsonism is strikingly different across populations. It is 
particularly prevalent in the Middle East and in North Africa, where it accounts 
for up to 13% and 41% of sporadic PD cases, respectively (108, 109). The 
frequency generally decreases with distance from the Mediterranean. This 
pattern is consistent with a common founder, whose diaspora disseminated the 
mutation (24). To date, five LRRK2 missense mutations that lead to Lrrk2 
protein substitutions have been proven to be pathogenic (p.R1441C, p.R1441G, 
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p.Y1699C, p.G2019S and p.I2020T). A variety of other mutations have been 
described, but they have not been conclusively proven to be pathogenic (110).  
 
The pathology in LRRK2 mutation carriers is probably LBD in most cases, 
though pure nigral cell loss with gliosis and tau pathology have also been 
reported (24, 104, 111-113). This highlights the fact that the clinical syndrome 
we refer to as PD may also be present in the absence of LBD (23) 
 
Given the apparent overlap between Lrrk2 p.G2019S parkinsonism and 
idiopathic PD, there has been much interest in LRRK2 as a candidate gene for 
genetic association studies in sporadic PD. Two comprehensive studies did not 
find LRRK2 variants to be associated with sporadic PD in Caucasian 
populations (114, 115). An early study in patients and controls of Chinese 
descent indicated that such ‘risk’ variants may exist in other populations (116). 
Indeed, it is now clear that the Lrrk2 p.G2385R substitution is consistently found 
in about 10% of PD patients versus 5% of controls in the Han Chinese 
population (117-122). A recent study pooling three patient-control series of 
Chinese descent have highlighted a second Lrrk2 substitution (p.R1628P) to be 
associated with susceptibility to PD in this population (123). Together with the 
insights from Lrrk2 p.G2019S parkinsonism these findings strongly emphasize 
the different effects of specific genetic variants in different populations. This may 
lead us to conclude that PD is a syndrome rather than a disease. 
 
ATPase type 13A2 (ATP13A2)  (PARK9 [OMIM #606693]) 
Kufor Rakeb syndrome (KRS) is a rare autosomal recessive, juvenile-onset 
parkinsonism. The disorder is responsive to levodopa, but patients suffer from 
atypical symptoms that include signs of pyramidal degeneration, upward gaze 
palsy, spasticity and dementia. KRS was first reported in a consanguineous 
Jordanian family (124). In 2001, the disease was mapped to chromosome 1p36 
(125). The disease-causing gene was found to be ATPase type 13A2 
(ATP13A2) when a compound heterozygous deletion (exon 26: delC3057; 
G1019fsX1021) and splice site (exon 13: 1306+5G>A) mutation was identified 
in affected members of a large Chilean family. This study also identified a 
homozygous 22 bp duplication (exon 16: 1632_1653dup22 Leu552fsX788) in 
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affected members of the original Jordanian family (126). These mutations lead 
to loss of function in the 1,180 amino acid ATP13A2 protein, and a link between 
aggregation of mutant protein in the endoplasmic reticulum and proteasomal or 
lysosomal dysfunction has been suggested (126). Di Fonzo et al. reported a 
homozygous missense mutation (exon 15: 1510G>C; Gly504Arg) in one 
juvenile parkinsonism patient with disease-onset at age 12 years and it is 
possible that this variant is the cause of disease (127). This study also identified 
two further heterozygous variants (exon 2: 35C>T; Thr12Met & exon 16: 
1597G>A; Gly533Arg) in EOPD patients. However, the role of this gene in PD 
has yet to be resolved. 
 
PARK11 [OMIM %607688]) 
Linkage to 2q in a sample of sib pairs with PD was reported in 2002 (128). The 
authors expanded on their work by showing that the evidence for a 
chromosome 2q36-q37 PD susceptibility gene was primarily due to families with 
a strong family history of PD. A strong family history of PD being defined as at 
least 4 affected family members or an affected sib pair with an affected parent 
(129). Very recently, heterozygous missense mutations in the Grb10-Interacting 
GYF Protein-2 (GIGYF2) gene within the PARK11 locus were reported (130). 
The families included in the study did not show definitive co-segregation with 
disease. Further studies are needed to clarify the role of GIGYF2 in PD.  
 
OMI/HTRA serine peptidase 2 (PARK13 [OMIM *606441]) 
Strauss et al. first reported the presence of mutations within the OMI/HTRA2 
gene in PD patients (131). The gene is located within the PARK3 linkage region 
on chromosome 2p13, and it encodes a 458 amino acid protein that is reported 
to function as a serine protease (132). 
  
A missense mutation 1195G>A resulting in a p.G399S amino acid substitution 
in the protein was observed in four sporadic PD patients and was not seen in 
370 healthy controls. The p.G399S patients share a haplotype, suggesting a 
common ancestor (131). p.G399S is located in the PDZ binding domain of the 
protein and may result in decreased protease function. A second 421G>T 
variant that results in a p.A141S substitution was reported to be associated with 
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increased risk of disease. The p.A141S substitution was observed in 6.2% of 
PD patients (n=414) versus 3% of controls (n=331). A recent comprehensive 
study sequenced the entire coding region of OMI/HTRA2 in a series of 644 
North American PD cases with both young- and late-onset disease and in 828 
North American neurologically normal controls. The results showed that neither 
of the variants previously related to PD were associated with PD in this large 
cohort and that the risk variants were present in neurologically normal controls 
(133). 
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1.8 Parkinson’s disease as a complex trait 
 
 
 
 
Figure 2. Model of the relationship between allele frequencies and effect size in complex traits.  
Mendelian genes may be rare, but they exert a significant biological effect and may be the sole 
cause of disease in some cases. ‘Risk alleles‘ are commonly found in the population and are 
associated with a modest increase in disease risk, e.g. odds ratio (OR) ≤ 2.0.  
Despite the tremendous progress in PD genetics over the past 11 years, the 
cause of disease remains unaccounted for in most PD patients. Genetic 
association studies have been utilized to investigate differences in allele 
frequency in PD patient and control series. The goal of such studies is to 
identify marker alleles whose frequencies are significantly different between 
cases and controls, and thus may be associated with susceptibility to disease. 
Association studies may potentially have better power to detect subtle effect 
sizes (Figure 2) as traditional linkage studies cannot detect subtle effects, i.e. 
ORs ≤ 2.0 (134). The manifestation of disease may be a result of several such 
genetic and possibly environmental risk factors. Investigating ‘candidate genes’ 
is a widely used approach in genetic association studies, because these 
methods are widely available and relatively inexpensive; see www.PDGene.org 
for an updated collection of genetic association studies in PD. However, 
‘candidate gene’ studies may not be the best approach as it is hard to select the 
best candidates among the >25,000 genes in the human genome. This may be 
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a particularly relevant problem in PD, where we have limited a priori insight into 
the key molecular players involved in neurodegeneration. Indeed, the main goal 
of genetic mapping studies is to identify these molecular players in the first 
place. This may explain the fact that the most convincing associations between 
markers and susceptibility to PD have been discovered in the familial 
parkinsonism genes SNCA and LRRK2 (see previous section). Possible 
solutions to the problem of ‘not knowing where to start’ when investigating ‘risk-
alleles’ may include fine-mapping within genetic loci identified through linkage 
studies, genome wide association (GWA) studies and candidate gene 
approaches based on insight from familial genes.
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 2. Aims of the studies 
Paper I 
• Describe the pattern of LD within the PARK10 locus by genotyping 
SNPs across the locus. 
• Increase the number of SNPs in the region until reasonable coverage of 
the genetic variability within PARK10 was achieved. 
• Identify markers that are associated with susceptibility to PD 
• Follow-up on findings from other studies that have nominated candidate 
genes within PARK10. 
 
Paper II 
• Replicate a reported association between AAO in PD and SNPs in the 
ELAVL4 gene (Nouriddine et al., 2005) 
• ELAVL4 is located within the PARK10 locus. Consequently, we wanted 
to investigate whether genetic markers within the gene were associated 
with susceptibility to PD. 
 
Paper III 
• The first GWA-study in Parkinson’s disease nominated two PARK10 
SNPs to be associated with susceptibility to PD, so we attempted to 
replicate this finding and fine-map the region surrounding these two 
SNPs (Maraganore et al., 2005) 
• Replicate the other 11 SNPs nominated by the GWA-study. 
 
Paper IV 
• Assess whether genetic variability across the Leucine-rich repeat 
kinase 1 (LRRK1) gene, the only human homologue of the important 
LRRK2 gene, is associated with susceptibility to PD in the Norwegian 
population. 
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3. Materials 
3.1 Human subjects 
All four papers included in this thesis made use of DNA and clinical data 
obtained from PD patients and control subjects: 
 
PD patients and controls from central Norway 
A clinical based series now consisting of >600 PD patients from central Norway 
has been recruited since 1998. 530 unrelated PD patients were included in 
Paper I (Table 5). All patients have been examined and followed longitudinally 
by one movement disorder neurologist (Jan O. Aasly) at the outpatients clinics 
of three hospitals in central Norway; St. Olav’s Hospital (Trondheim University 
Hospital), Ålesund Hospital (Ålesund) and Helgeland Hospital (Mosjøen). The 
patients were referred from general practitioners or other hospitals. Patients 
reporting a family history of PD were asked to inform family members of this 
ongoing study. All patients and family members willing to do so were invited to 
take part in the study. 
 
A medical history, including a family history was obtained from each patient. 
Each patient underwent neurological examination, including the Unified PD 
Rating Scale (UPDRS) and Hoehn and Yahr staging (135, 136). The clinical 
interview and the Mini Mental State Examination (MMSE) were used to assess 
cognitive impairment (137). The clinical presentation was consistent with a 
diagnosis of possible or probable PD according to the criteria proposed by Gelb 
et al. (22). Patients with atypical symptoms such as severe autonomic 
dysfunction, early dementia, unfavorable response to levodopa therapy and 
supranuclear gaze palsy were excluded. The patient assessment included 
routine laboratory tests. Blood samples were also obtained for DNA extraction. 
 
A total of 1143 controls were also collected as a part of the ongoing study. 
These were healthy individuals with no signs of neurodegenerative disease and 
no family history of PD. About 50% of the controls genotyped in Paper IV were 
recruited through an ongoing study on dementia in the Trondheim region by a 
second neurologist (Sigrid B. Sando). 
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Table 5. Demographics for patients and controls in Paper I (Stage 3) 
Variable PD cases Controls 
Norwegian samples n = 530 n = 1,142 
Age 72 ± 11 (29 – 98) 73 ± 11 (29 – 98) 
Gender   
Male 324 (61%) 541 (47%) 
Female 206 (39%) 601 (53%) 
Age at onset (AAO) 59 ± 11 N/A 
Irish samples n = 173 n = 173 
Age 61 ± 12 (33 – 90) 61 ± 12 (33 – 90) 
Gender   
Male 70 (40%) 70 (40%) 
Female 103 (60%) 103 (60%) 
Age at onset (AAO) 50 ± 11 (18 – 77) N/A 
US samples n = 221 n = 221 
Age 70 ± 10 (36 – 89) 70 ± 10 (36 – 89) 
Gender   
Male 106 (48%) 106 (48%) 
Female 115 (52%) 115 (52%) 
Age at onset (AAO) 62 ± 12 (23 – 85) N/A 
The sample mean ± SD years (range) is given for age and age at PD onset.  
 
PD patients and controls from Ireland 
Papers II-IV include DNA obtained from 186 PD patients and 186 controls from 
Ireland. The Irish patients were examined and followed longitudinally by two 
movement disorder neurologists (Timothy Lynch and J. Mark Gibson). PD was 
diagnosed according to the Gelb criteria (22). Controls were also ethnic Irish 
and individually matched to a patient by age (± 4 years) and gender. 
 
PD patients and controls from Mayo Clinic Jacksonville 
DNA from samples included in Papers II-IV was also collected at the 
Department of Neurology, Mayo Clinic Jacksonville. These were Caucasian 
individuals of European decent. Patients were examined and followed by to 
movement disorder neurologists (Ryan J. Uitti and Zbigniew K. Wszolek). PD 
was diagnosed according to published criteria (22). Controls recruited from 
Mayo Clinic Jacksonville had no evidence of neurodegenerative disease.  
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4. Methods 
4.1 Molecular biology 
DNA was extracted from whole blood using standard protocols.  
For Paper I genotyping was conducted by PCR amplification using one primer 
pair for each SNP. PCR products were digested with restriction enzymes and 
resulting fragments separated by agarose gel electrophoresis. Additional 
genotyping was performed by running available and designed (Available-by-
Design or Available-by-Demand) TaqMan chemistry on an ABI7900 (Applied 
Biosystems, Foster City, CA, USA) and analyzed with SDS 2.2.2 software. In 
cases where genotype data was only available for one sample of a matched 
pair, the other subject was retained in the analysis. TaqMan chemistry was also 
used for the genotyping in Papers II-IV, including positive controls for mutation 
screening in Paper IV. Mulitplexed genotyping of SNPs for the last part of Paper 
I (Stage 3) was performed on a Sequenom MassArray iPLEX platform (San 
Diego, CA). 
 
4.2 Statistical methods 
Association 
Genetic association examines whether single-locus alleles or genotype 
frequencies differ between the patient and control groups. In Papers I-III we 
used logistic regression to estimate odds ratios (ORs) and the corresponding P-
values for each marker. In Paper IV the association was tested using Pearson’s 
chi-square test. In paper I-III we used permutations to correct for multiple testing 
(138). 
 
Linkage disequilibrium (LD) mapping 
Pairwise LD between markers was assessed by calculating r2 as implemented 
in Haploview software (139). In addition we constructed a LD-unit (LDU) map 
across the locus of interest in Paper I and III using the LDMAP software (140). 
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4.3 Ethical considerations 
All individuals who participated in the studies provided informed consent. Study 
protocols for the samples from central Norway were approved by the Regional 
Committee for Medical Research Ethics in Central Norway. Studies conducted 
at Mayo Clinic Jacksonville were approved by the Mayo Clinic Institutional 
Review Board (IRB). The Irish collaborators also have IRB approval. The 
biobanks in Trondheim have approvals in compliance with the Norwegian 
Biobank Law. 
 
 43 
5. Results 
5.1 Review of Paper I 
 
Fine-Mapping and Candidate Gene Investigation within the PARK10 Locus 
Kristoffer Haugarvoll, Mathias Toft, Lisa Skipper, Michael G. Heckman, Julia E. 
Crook, Alexandra Soto, Owen A. Ross, Mary M. Hulihan, Jennifer M. 
Kachergus, Sigrid B. Sando, Linda R. White, Timothy Lynch, J. Mark Gibson, 
Ryan J. Uitti, Zbigniew K. Wszolek, Jan O. Aasly, and Matthew J. Farrer 
 
Background: PARK10 has been linked to LOPD in Iceland. We investigated 
associations between SNPs within the PARK10 locus and susceptibility to PD or 
AAO of PD. 
 
Methods and results: One-hundred and eighty-eight SNPs were genotyped 
across the PARK10 locus in 180 PD patients and 180 controls from central 
Norway (Stage 1). The pattern of LD from stage 1 was used to select 75 SNPs 
for genotyping in 186 patients and 186 controls from Ireland (Stage 2). Finally, 
we selected 19 SNPs from this and previous studies for follow-up in an 
extended Norwegian series (530 patients and 1,142 controls), the Irish series 
and a US series (221 patients and 221 controls) (Stage 3). In the overall 
combined series, associations with PD are significant for two SNPs in the 
USP24 gene (rs13312: OR 0.78; P≤0.001, rs487230: OR 0.80; P=0.001) after 
correction for multiple testing. The association trends are comparable across 
the series included in this study. No marker showed consistent association with 
AAO. Markers in other candidate genes were not associated with susceptibility 
to PD. 
 
Conclusion: The USP24 SNPs included herein were previously reported to be 
associated with PD. Our data indicate that USP24 may indeed be implicated in 
PD. However, the observed effect size does not explain the PARK10 linkage 
peak. 
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5.2 Review of Paper II 
 
ELAVL4, PARK10 and the Celts 
Kristoffer Haugarvoll, Mathias Toft, Owen A. Ross, Jeremy T. Stone, Michael G. 
Heckman, Linda R. White, Timothy Lynch, J. Mark Gibson, Zbigniew K. 
Wszolek, Ryan J. Uitti, Jan O. Aasly, and Matthew J. Farrer 
 
Background: Genetic variation within the gene encoding ELAVL4 (embryonic 
lethal, abnormal vision-like protein) was reported to be associated with AAO in a 
familial series of PD patients originating from the United States. 
  
Methods and results: We examined 5 SNPs spanning the ELAVL4 gene in 
Norwegian, American, and Irish PD patient–control samples. No association 
was found between the examined markers and AAO or PD in Norwegian or 
American samples. However, ELAVL4 markers (rs967582; OR 1.53, CI 1.13-
2.07, P=0.007 and rs3902720; OR 1.55, CI 1.14-2.13, P=0.006) were 
significantly associated with susceptibility to PD in our Irish series. This 
association is significant after correction for multiple testing.  
 
Conclusion: Our data suggest that the association between ELAVL4 and 
susceptibility to PD previously observed may be explained by a Celtic-founder 
effect. However, independent replication is needed to confirm ELAVL4 as a 
population-specific risk factor and exclude the possibility of a spurious 
association. 
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5.3 Review of Paper III 
 
Genome wide association, Parkinson’s disease, and PARK10 
 
Matthew J. Farrer, Kristoffer Haugarvoll, Owen A. Ross, Jeremy T. Stone, 
Nicole M. Milkovic, Stephanie A. Cobb, Andrew J. Whittle, Sarah J. Lincoln, 
Mary M. Hulihan, Michael G. Heckman, Linda R. White, Jan O. Aasly, J. Mark 
Gibson, David Gosal, Timothy Lynch, Zbigniew K. Wszolek, Ryan J. Uitti, and 
Mathias Toft 
 
Background: The first genome wide association (GWA) study in PD nominated 
13 SNPs to be associated with susceptibility to disease. Two of these SNPs 
were in LD in the CUB domain containing protein 2 (CDCP2) gene. CDCP2 
(previously known as LOC200008) is located within the PARK10 locus. 
 
Methods and results: We genotyped 28 SNPs (including rs682705 and 
rs7520966) within a 132 kb interval around CDCP2 in patient-control samples 
from Norway and Ireland. rs682705 and rs7520966 were also genotyped in a 
US series. In addition, we attempted to replicate the 11 ‘top-hits’ from the GWA-
study. There was no evidence of association with susceptibility to PD for any the 
28 CDCP2 SNPs. None of the other 11 SNPs nominated by the GWA-study 
were associated with PD in our samples, independently or as a combined 
sample set. No marker was associated with age at onset (AAO). 
 
Conclusion: The negative findings in this study indicate that the conclusions 
derived from the first GWA-study in PD may be based on spurious associations. 
These findings highlight the need for independent replication of association 
studies. 
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5.4 Review of Paper IV 
 
Variants in the LRRK1 gene and susceptibility to Parkinson's disease in 
Norway 
Kristoffer Haugarvoll, Mathias Toft, Owen A. Ross, Linda R. White, Jan O. 
Aasly, and Matthew J. Farrer 
 
Background: The identification of LRR2 gene mutations as an important cause 
of LOPD has highlighted the genetic component of this disorder. The Lrrk2 
p.G2019S substitution has been identified in nine Norwegian families. LRRK1 is 
the single homologue of LRRK2, indicating that their gene products share 
functions and pathways. A sequencing study in probands from PD families 
identified four novel missense variants in the LRRK1 gene, one of them in a 
Norwegian proband. 
 
Methods and results: We investigated whether five SNPs or the four novel 
missense variants are associated with susceptibility to PD in the Norwegian 
population. The nine markers were genotyped in 338 PD patients and 338 
matched controls from central Norway. In addition, we genotyped the same 
markers in 249 further unmatched controls. Two rare coding variants; 
ss65713826 (p.K203E) and ss65713830 (p.T967M), were more frequent in 
patients than controls, However, this difference was not significant after 
correction for multiple testing. 
 
Conclusion: The identification of disease-causing mutations in presenilin 1 and 
2 in Alzheimer’s disease shows that homologous proteins can cause the same 
disease phenotype. Two rare LRRK1 coding variants; ss65713826 (p.K203E) 
and ss65713830 (p.T967M) were more frequent in patients than controls, but 
their identification in healthy controls and lack of co-segregation with disease 
suggest they may represent benign variants. Thus, we found no evidence 
implicating LRRK1 in the etiology of PD. 
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6. Discussion 
6.1 Fine-mapping within the PARK10 locus 
The PARK10 locus was first linked to LOPD in Iceland (141). Li et al. linked an 
overlapping locus to AAO in the US population (142). Population history and 
genetic analysis of X- and Y-chromosomal markers have shown that the 
Icelandic population is mostly of Scandinavian descent, with a minor Celtic 
matrilineal contribution (143, 144). We hypothesized that if a PARK10 mutation 
antedates the settlement of Iceland, this mutation may be identified in the 
Norwegian or Irish population. In Paper 1, we investigated this by fine-mapping 
188 SNPs across the maximum LOD score minus one (LOD-1) interval in 180 
PD patients and controls from Norway (Stage 1). Subsequently, 75 of those 
SNPs were selected based on the LD structure from Norwegian controls in 
Stage 1, to investigate the locus in 186 patients and 186 controls from Ireland 
(Stage 2). Markers that showed evidence of association with susceptibility to PD 
(P≤0.05) were selected for genotyping in Stage 3. Stage 3 included an extended 
Norwegian series (530 patients and 1,142 controls), the Irish series and a series 
from the US (221 patients and 221 controls). None of the SNPs from the fine-
mapping studies (5 from Stage 1, Norwegian; and 2 from Stage 2, Irish) was 
associated with susceptibility when followed-up in the extended series.  
 
These results indicate that initial associations from Stages 1 and 2 were 
spurious, and highlight the need for replication in association studies. Our fine-
mapping series did not have power to detect subtle effects. However, Hicks et 
al. estimated that carriers of one PARK10 ‘risk allele’ have 30 times increased 
risk of PD compared to non-carriers (141). We estimated that the fine-mapping 
series used in Paper I (Stages 1 and 2) had 80% power to detect ORs≥1.9 at 
the 5% significance level. This assumes an additive model with minor allele 
frequency (MAF) ≥10%. We genotyped more than one SNP every 50 kb. This is 
not sufficient to capture all genetic variability within the PARK10 locus. 
However, LD in a United States population of north-European descent was 
shown to typically extend 60 kb from common alleles (145). Empirical data from 
the LRRK2 gene tells us that most carriers of the common c.6055G>A mutation 
(p.G2019S) mutation share an ancestral haplotype spanning between 145 to 
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154 kb around the mutation (106). Likewise, carriers of the Chinese ‘risk allele’ 
c.7153G>A (p.G2385R) share a 239 to 294 kb haplotype around the disease- 
associated allele (119). These observations demonstrate that LD-mapping may 
indeed be possible for PD associated alleles that occur frequently in a 
population using the SNP density employed in Paper I. A caveat of the 
approach taken in Paper I is that a gene containing several mutations, each with 
low individual frequency, may not be detected. 
 
6.2 Candidate gene investigation within PARK10 
Papers I-III investigated SNPs in candidate genes within the PARK10 locus. 
Several studies had investigated PARK10 for SNPs that are associated with 
susceptibility to PD or AAO, nominating several genes during the course of our 
fine mapping study; human immunodeficiency virus type I enhancer binding 
protein 3 (HIVEP3) (146, 147), eukaryotic translation initiation factor 2B, subunit 
3 gamma (EIF2B3) (147), embryonic lethal, abnormal vision-like 4 (ELAVL4)  
(148) and ubiquitin specific peptidase 24 (USP24) (147, 149). A recent genome-
wide association study in PD identified two PARK10 SNPs in LD within the CUB 
domain containing protein 2 (CDCP2) gene (150). Furthermore, a gene 
expression study recently highlighted ring finger protein 11 (RNF11) as a 
PARK10 candidate gene (151). It remains unresolved whether any of these 
candidate genes could account for the PARK10 linkage or are involved in the 
etiology of PD.  
 
In paper II we investigated 5 SNPs within the ELAVL4 gene. These markers had 
previously been associated with AAO in PD by Noureddine and colleagues 
(148). We could not replicate the association between these markers and AAO. 
The use of AAO as a quantitative trait in genetic association studies may be 
questionable, e.g. the AAO may differ by decades even in LRRK2 mutation 
carriers from the same family. Furthermore, most PD cases have an AAO 
around 60 years and one may need two large groups that have distinctly 
younger and older AAO, respectively, in order to make an AAO approach work. 
These problems may explain why the group that originally reported ELAVL4 
markers to be associated with AAO could not replicate their own findings in a 
follow-up study (147, 148). In contrast, we found two ELAVL4 SNPs (rs967582 
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and rs3902720) to be significantly associated with susceptibility to PD in the 
Irish population, after correction for multiple testing. No ELAVL4 SNP is 
associated with PD in the Norwegian or US series. This lack of consistency may 
be due to a population specific effect. The Lrrk2 p.G2385R ‘risk’ substitution in 
the Asian population is an example of such population specific effects (117-
122). Alternatively, the observed association in the Irish series may be spurious. 
Independent replication is imperative to resolve this issue (152, 153). 
 
In Paper I, we found no evidence of association between HIVEP3 SNPs and 
susceptibility to PD. This is inconsistent with two previous reports including the 
same markers (146, 147). However, these two studies included essentially the 
same samples, and so do not represent independent replication of the initial 
finding (147). Maraganore et al. also examined two of the HIVEP3 SNPs in their 
GWA-study, but the results were inconsistent for the two HIVEP3 SNPs in the 
two tiers (150). Together with our results, this does not support a role for 
HIVEP3 in the etiology of PD.  
 
SNPs in the RNF11, EIF2B3 and CDCP2 genes were not associated with 
susceptibility to PD in our studies (Papers I and III, respectively). Furthermore, 
we found no association with markers in EIF2B3 and USP24 and AAO (Paper 
I). 
 
6.3 Association between USP24 SNPs and PD 
SNPs within the USP24 gene are associated with susceptibility to PD in the 
combined Norwegian, Irish and US series; see paper I. The association is 
significant for two markers. Joint analysis of the Norwegian, Irish and US series 
was significant after correction for multiple testing for rs13312 (OR: 0.78, 95% 
CI: 0.67 – 0.90, P=0.0007) and rs487230 (OR: 0.80, 95% CI: 0.70 – 0.91, 
P=0.0013), whereas rs287235 (OR: 0.81, 95% CI: 0.71 – 0.93, P=0.0035) and  
rs1165226 (OR: 0.86, 95% CI: 0.76 – 0.97, P=0.015) showed the same trend. In 
the Norwegian series all four SNPs in USP24 were individually associated with 
susceptibility to PD. However, the association trends were not significant after 
correction for multiple testing. Interestingly, the Irish series showed identical 
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ORs for USP24 SNPs and there was a similar, albeit weaker, effect in the US 
series. However the associations were not significant in these smaller samples.  
A previous study in the US population first nominated markers in USP24 to be 
associated with susceptibility to PD (149). Our data supports a role for this gene 
in the etiology of PD. Nevertheless, the association between USP24 SNPs and 
PD does not explain the PARK10 linkage peak, as linkage studies do not have 
the power to detect subtle effect sizes, e.g. ORs≤2 (134). Thus, independent 
replication in a well-powered patient-control series is warranted to establish the 
role of USP24 in PD. 
 
6.4 Genome wide association (GWA) studies in PD 
Maraganore et al. conducted the first GWA-study in a US Caucasian PD 
population. They employed a two-tiered study design: In tier 1, 443 sibling pairs 
(n= 886) discordant for PD were genotyped for 198,345 SNPs (172,420,019 
genotype calls). In tier 2, an independent patient-control series was used to 
follow-up the strongest 1,892 associations (150). Eleven SNPs showing 
strongest evidence of association were nominated to be involved in the etiology 
of PD, in addtion to the 2 PARK10 SNPs discussed above. In paper III we 
attempted to replicate these findings, but none of these SNPs was associated 
with susceptibility to PD in our study. Several other groups have also failed to 
support the original findings (154-159). One conclusion from this work is that 
there may be no major ‘global’ risk factor for PD (e.g. a risk allele with OR >2). 
In contrast, such ‘risk’ alleles were recently identified in another common 
movement disorder, restless legs syndrome (RLS) through GWA-studies (160-
163).  
 
The associations between common polymorphisms in the SNCA gene and PD 
across populations indicate that variants with smaller effects do exist (e.g. 
ORs≤1.5). However, GWA-studies need substantially better power to be able to 
detect these subtle effects (164, 165). Power is particularly important in GWA-
studies, as correction for multiple testing is essential when genotyping >200,000 
SNPs. There is no consensus on how best to perform correction for multiple 
testing in GWA-studies. The Bonferroni correction is inappropriate in GWA-
studies as it assumes independent tests. In GWA-studies, however many SNPs 
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are dependent on each other due to some degree of LD between them. 
Permutations, as used in Papers I-IV, may be more appropriate (166). A second 
GWA-study in PD has now been published (167). As this study used a small 
US-series of 267 PD patient and 270 controls, little additional insight could be 
derived from it. GWA-studies may yet provide insight into the etiology of PD if 
we build on the experiences gained from the first studies.  A powerful GWA-
study in PD has not been performed to date. Alternatively, future studies may 
employ more homogenous populations, EOPD patients or endophenotypes 
(e.g. tremor dominant PD) (168-170). 
 
6.5 Linkage and candidate gene studies 
In Paper IV we investigated genetic variants in the Leucine-rich repeat kinase 1 
(LRRK1) gene in Norwegian PD patients and controls. LRRK1 is the single 
homolog of LRRK2 (171-173), and the Lrrk2 p.G2019S substitution has been 
shown to be an important cause of PD in Norway (106, 174, 175).  We know 
from presenilin 1 and 2 in Alzheimer’s disease (AD) that homologous proteins 
can cause the same neurodegenerative syndrome (176, 177). In paper IV, we 
found no evidence implicating LRRK1 variants in the etiology of PD in 
Norwegian patients (173).  
 
To date, familial linkage studies have been the most successful method to 
identify the molecular players involved in neurodegeneration. GWA-studies 
currently generate much enthusiasm, but if they only detect very subtle effects 
(e.g. ORs≤1.5) it is pertinent to ask to what degree they provide us with useful 
insight (178). In contrast, Mendelian forms of parkinsonism with large effect 
sizes (e.g. ORs >10) may only make up a small proportion of the entire PD 
population, though the biological insights derived from these discoveries can 
hardly be overstated, and genes with large effects are probably far more useful 
for functional studies and the generation of disease models (179, 180). 
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7. Conclusions 
From the studies presented herein we have gained new and important 
knowledge about the genetics of PD and provided hints on how best to conduct 
genetic studies in the future. Furthermore, our work highlights the need for 
caution when interpreting the results from novel methods and that independent 
replication is pivotal when assessing the importance of a scientific finding: 
 
• We identified no genetic variant exerting a major effect on PD risk within 
the PARK10 locus (Papers I-III). This could be because the finding from 
the initial study nominating the locus may represent an artifact. More 
focus on familial studies to replicate linkage and identifying novel loci 
may be fruitful. Thus far, linkage has been the single most effective 
method to identify genetic causes of disease. 
 
• However, we did identify markers in the USP24 gene that are 
associated with susceptibility to PD. Our finding is in agreement with a 
previous study. The effect of these variants is modest, corresponding to 
ORs 1.20-1.22 for the major allele. Independent replication is needed to 
establish the role of USP24 variants in the etiology of PD. Our results 
indicate that USP24 may contain ‘risk’ alleles that are independent of 
PARK10. We also identified ELAVL4 as a possible population specific 
‘risk’ gene in PD, a finding that also warrants replication (Paper II). 
 
• We and others, could not replicate the findings from the first GWA-study 
in PD despite comprehensive efforts (Paper III). Future GWA-studies 
may be fruitful if they build on insight derived from these early studies. 
Improvements may include substantially better power, studies in more 
homogenous populations and investigations of endophenotypes. 
 
• LRRK1 is the single homolog of LRRK2, and thus an excellent 
candidate gene for PD. Nevertheless, our results indicate that this gene 
does not seem to play a major role in the etiology of PD in Norway 
(Paper IV). 
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If independent studies replicate the findings from Papers I or II, PD may truly be 
classified as a complex trait, i.e. multiple modest risk factors (genetic and 
environmental) may be needed to jointly produce disease. This may have 
impact on future study design, as substantial power will be needed to identify 
such modest risk factors. 
 
It is, however pertinent to ask what insight may be gained from such modest risk 
factors. They will not be meaningful for genetic counseling and may contribute 
little to functional research compared with Mendelian genes. Conversely, the 
identification of multiple ‘risk’ variants paired with increased insight into the 
normal function of proteins may highlight pathways involved in 
neurodegeneration. 
 
‘Translation’ is a popular term in modern medicine. Basic research can generate 
knowledge about the process of neurodegeneration and may help create the 
platform necessary to achieve translational breakthroughs. Genetic research 
may be one way of achieving further insight. This will hopefully lead to 
substantially improved treatment in the future. 
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Genomewide Association, Parkinson Disease, and
PARK10
To the Editor:
Genomewide linkage analysis of rare familial forms of
parkinsonism has identified mutations in seven genes,
revealing a clinicopathologically and genetically hetero-
geneous syndrome.1 Less progress has been made in the
more typical late-onset form of Parkinson disease (PD
[MIM 168600]), although the recently identified LRRK2
(MIM 609007) G2019S substitution is estimated to ac-
count for ∼1% of sporadic PD cases.2 Common poly-
morphisms of familial genes may also influence suscep-
tibility to idiopathic PD.3,4 Of the 198,345 SNPs suc-
cessfully genotyped in the recent genomewide associa-
tion (GWA) study, 26 had notably different allele fre-
quencies between patients and controls in both tiers
( ).5 Fifteen of these SNPs had opposite directionsP ! .01
of effect (disease risk or protection) in tiers 1 and 2. The
remaining 11 SNPs were proposed as markers for new
genes/chromosomal loci that influence susceptibility to
PD. In addition, two SNPs in tier 2 (rs682705 and
rs7520966) were highlighted in the PARK10 locus
(MIM 606852), which nominated the gene LOC200008
in disease susceptibility.
The PARK10 locus on chromosome 1p32 was origi-
nally identified in a genomewide linkage analysis of 117
patients from 51 Icelandic families (maximum Z plr
at D1S231, with a LOD-1, 7.6-cM support interval4.8
from D1S2874 to D1S475).6 Iceland has a well-char-
acterized genealogy that is powerful for family-based
linkage studies. The ancestral founders of Iceland have
Scandinavian patrilineal inheritance with a minor Celtic
matrilineal component.7 Assuming that the PARK10
mutation predates the Icelandic settlement, we reasoned
that the 1p32 susceptibility gene might be more readily
found in patients with PD originating from Scandinavian
or Celtic populations. In parallel to the study of Mar-
aganore et al.,5 we have been mapping the PARK10 lo-
cus. Genotypes from 28 SNPs (including rs682705 and
rs7520966) within a 132-kb region of chromosome
1p32 located around the LOC200008 gene have been
analyzed in two well-characterized case-control series
from Norway and Ireland. In addition, we attempted to
replicate findings for the two PARK10 SNPs in a U.S.
series collected at the Mayo Clinic in Jacksonville, FL.
We then employed all three case-control series to inves-
tigate the genotype/allele frequencies of the main 11
SNPs nominated to influence PD susceptibility.5 Power
was comparable to the original study (180% at ap
for odds ratios [ORs] 12.0 and for disease-allele0.05
frequencies 10.035), and genotyping call rates were
195% for all markers (table 1).
In total, Norwegian samples included 676 subjects
(cases and controls) with a mean age (SD) of 70 11
years, Irish samples included 372 subjects with a mean
age (SD) of 61  13 years, and the U.S. samples in-
cluded 522 subjects with a mean age (SD) of 71 10
years. All patients were examined and were observed lon-
gitudinally by a movement-disorders neurologist (J.O.A.,
J.M.G., D.G., T.L., Z.K.W., and R.J.U.), and they were
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Table 1
Genotype/Allele Frequencies of the Main 11 SNPs
Nominated to Influence PD Susceptibility
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
given a diagnosis of PD in accordance with published
criteria.8 Each patient was individually matched, on the
basis of age (4 years) and ethnicity, to an unrelated
control without evidence of neurological disease. The
ethical review boards at each institution involved ap-
proved the study, and all participants provided informed
consent.
SNP genotyping was performed using TaqMan chem-
istry on an ABI7900 genetic analyzer; in cases where
genotype data was available for only one subject of a
matched pair, the other subject was retained in the anal-
ysis. For the controls in each population, x2 tests of
Hardy-Weinberg equilibrium (HWE) were implemented
using Haploview.9 Optimal SNP coverage for association
analysis of the LOC200008 gene was determined em-
pirically by the construction of linkage-disequilibrium
(LD) maps in Norwegian and Irish samples, onto which
haplotype blocks were assigned (fig. 1).10,11 ORs for dis-
ease association, with corresponding 95% CIs, were sub-
sequently calculated using logistic-regression models ad-
justed for age and sex. Overall ORs combining data from
all three sites were additionally adjusted for site. Pre-
vious studies have nominated the PARK10 locus as an
age-at-onset modifier in PD12; thus, we also assessed the
influence of 1p32 SNPs variability on this disease trait,
using linear-regression models adjusted for sex.
There was no evidence of association with PD for any
of the 28 genotyped 1p32 SNPs in our study (all SNP
after applying Bonferroni correction in bothP 1 .05
population samples). Haplotype frequencies between pa-
tients and controls were not significantly different for
the haplotype blocks identified; nor was the age at on-
set in patients associated with any single marker or
haplotype (all corrected ). Of note, the ancestralP 1 .05
recombination and haplotype blocks apparent within
Norwegian and Irish samples were comparable for this
interval at this marker resolution. The average number
of SNPs per LD unit (LDU) was 6.8 (mean LDU between
markers 0.15, range 0–0.63), indicating that the number
of SNPs genotyped within and flanking LOC200008
should be sufficient for examination of the region.11 In
addition, the two PARK10 SNPs showed no significant
association within the U.S. series ( ). None of theP 1 .05
other 11 SNPs nominated by the GWA study had different
allele frequencies or genotype distributions between af-
fected subjects and matched controls (all SNP inP 1 .05
all populations independently or as a combined sample
set) (table 2). There was no evidence of departure from
HWE in controls ( in all population controls).P 1 .01
Our study indicates that genetic variability within the
LOC200008 gene is unlikely to explain the PARK10
susceptibility locus for PD. Sadly, the lack of disease
association and replication in an independent U.S. series
of comparable power suggests that the original findings
may be spurious. Failure to nominate LOC200008 as
the PARK10 gene in our population samples provides
empirical support for statistical caveats concerning GWA
studies. Implicit in multiple testing is false discovery,
even in well-designed studies, and there are several po-
tential sources of bias.13 Of note, neither PARK10 SNP
rs682705 nor rs7520966 fulfilled the main criterion for
being genotyped in tier 2 ( in tier 1 overall anal-P ! .01
ysis), but each was included with a less stringent associ-
ation criterion ( in tier 1 overall analysis) becauseP ! .05
of its physical position within a PARK locus. Interestingly,
the combined P value for rs682705 ( )6Pp 9.07# 10
is the second-lowest P value of the overall study, even
though it did not fulfill the inclusion criteria. Individual-
level data from the GWA study is not yet available, but,
in our study, these two SNPs also appear to be in LD
(pairwise ), as suggested by Maraganore et al.5;2r 1 0.9
in addition, the minor-allele frequencies (MAFs) of the
two SNPs are comparable across studies and popula-
tions. The former suggests less-than-optimal haplotype
tagging in the initial study, whereas the latter argues
against technical errors in genotyping, but neither pro-
vides sufficient explanation for the positive findings ob-
served elsewhere.5
We found no evidence of direct association between
the 11 SNPs nominated in the GWA study and disease
in the three independent populations or in a combined
sample group ( ) (table 2). However, for thesenp 1,570
loci, we did not employ a gene-based approach (nor did
we fine-map each region as with PARK10), as advocated
elsewhere14; we await the results of further replication
studies. Of note, in the study by Maraganore et al.,5 the
rs7702187 SNP within SEMA5A (MIM 609297) had
the lowest combined P value ( ); how-6Pp 7.62# 10
ever, a total of 53 SNPs were examined in this gene in
tier 1. Only rs7702187 was significant before correction
( ), which supports the possibly spurious naturePp .001
of this and the other associations. The MAFs observed
in our three populations and in that of the GWA study
are comparable, which argues against population bias/
heterogeneity (table 2).
The number of SNPs highlighted in each tier of the
original study is consistent with chance—that is, 1% of
SNPs use a significance level of . None of the PP ! .01
values obtained by Maraganore et al.5 meets a Bonfer-
roni correction for multiple testing, although this stan-
dard may be too conservative in GWA, since it fails to
account for LD and incorrectly assumes that chromo-
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Figure 1 Metric LD map and haplotype block structure of the investigated region. A, LD map providing information about LD patterns
in the investigated candidate region, through locations expressed in LDUs. LDUs have an inverse relationship with LD, with regions of extensive
recombination having many LDUs. The physical position of the gene in the region LOC200008 is marked with an arrow. All 28 SNPs genotyped
are reported, although the symbols () may be obscured for SNPs that lie in close physical proximity and high LD. SNPs rs682705 and
rs7520966 are denoted by an asterisk (*). B, LD structure of the candidate region. Black and dark gray cells, strong LD; gray cells, intermediate;
and light gray and white cells, evidence for historical recombination. The haplotype block structure of the region is defined according to Gabriel
et al.10 An asterisk denotes SNPs rs682705 and rs7520966. The LD map and haplotype structure were constructed using genotypes from the
Norwegian sample. Similar results were obtained for the Irish population.
somal markers are independent. A consensus on the most
appropriate correction for multiple testing has yet to be
reached. Now that genomewide data sets have been gen-
erated, there exists the possibility to use these to develop
appropriate statistical methods to identify true positive
results.15
In the interim, we recommend that enthusiasm for
positive findings should be tempered by the strength of
the evidence, the population-attributable risk, and the
differences in SNP allele/genotype frequencies between
cases and controls. If allele frequencies are significantly
different, genomic controls might be used to assess pop-
ulation substructure. It is important that future studies
employ multiple independent sample series, each with
sufficient power to verify significant genetic associations,
before publication.16 However, lack of evidence for an
association is not the same as evidence against one; thus,
lack of replication should also be interpreted with
caution.
Over the few next years, the number of GWA studies
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Table 2
11 SNPs Nominated in GWA Study as Genetic Susceptibility Loci for PD
dbSNP
ACCESSION
NUMBER CHROMOSOME
POSITION
(bp)
THIS STUDY MARAGANORE ET AL.5
Control MAF
Estimated OR
(95% CI)a
Combined
P
(np 1,570)
Control MAF P
Estimated OR
(95% CI)b
Combined P
( )np 1,550Ireland Norway United States Tier 1 Tier 2 Tier 1 Tier 2
rs7702187 5p15.2 9385281 .17 .18 .18 .88 (.74–1.06) .18 .18 .20 .001 .002 1.74 (1.36–2.24) 7.62 # 106
rs10200894 2q36 228642637 .13 .11 .09 .96 (.77–1.21) .74 .12 .13 .009 .001 1.84 (1.38–2.45) 1.70 # 105
rs2313982 4q31.1 139145665 .05 .11 .09 .93 (.73–1.18) .54 .07 .06 .006 .002 2.01 (1.44–2.79) 1.79 # 105
rs17329669 7p14 36625169 .13 .12 .14 1.01 (.82–1.24) .92 .13 .11 .008 .001 1.71 (1.33–2.21) 2.30 # 105
rs7723605 5p15.3 5407615 .13 .14 .13 .91 (.75–1.12) .38 .12 .09 .010 .002 1.78 (1.35–2.35) 3.30 # 105
ss46548856 10q21 58986929 .09 .08 .11 .93 (.73–1.19) .58 .09 .11 .003 .002 1.88 (1.38–2.57) 3.65 # 105
rs16851009 2q24 166456214 .11 .11 .12 .95 (.76–1.18) .63 .09 .08 .002 .009 1.84 (1.36–2.49) 4.17 # 105
rs2245218 1p36.2 13885132 .19 .17 .15 .95 (.79–1.14) .57 .11 .13 .002 .002 1.67 (1.29–2.14) 4.61 # 105
rs7878232 Xq28 150516943 .25 .23 .25 1.10 (.97–1.25) .15 .29 .26 .003 .010 1.38 (1.17–1.62) 6.87 # 105
rs1509269 4q31.1 139111329 .08 .13 .13 .94 (.76–1.17) .58 .10 .09 .005 .008 1.71 (1.30–2.26) 9.21 # 105
rs11737074 4q27 125438978 .21 .20 .21 1.05 (.89–1.25) .55 .19 .19 .007 .005 1.50 (1.21–1.86) 1.55 # 104
NOTE.—In this study, MAFs are not significantly different between the populations. No P values are corrected for multiple testing. SNPs are ordered by combined P value, per Maraganore
et al.5
a The direction of effect of the estimated OR observed in this study for each SNP is shown (i.e., 11 risk and !1 protective).
b Estimated ORs in the study by Maraganore et al.5 do not indicate the direction of effect relative to the MAF.
will increase, and it is important to learn from the ex-
periences gained by the few studies performed to date.
Although our negative findings suggest that the conclu-
sions drawn from the study by Maraganore et al.5 might
be based on spurious associations, further analysis of
individual-level raw data is now necessary. The recent
identification of a complement factor H polymorphism
in age-related macular degeneration in a GWA study and
the identical findings by two other groups using other
study designs demonstrates that this approach can be
used successfully.17–19 It may be that, because of the het-
erogeneous nature of PD, associations with a gestalt phe-
notype are masked by background variation in SNP in-
formativeness, population strata, and insufficient power.
It is, therefore, crucial that future associations are val-
idated and that analysis is performed to resolve the un-
derlying cause of association in the sample population.
GWA studies may still provide direction for the genetic
analysis of heterogenous complex traits, but, in the short
term, they may exacerbate the problem of replication
failure in association studies.
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No Evidence for Association with Parkinson Disease
for 13 Single-Nucleotide Polymorphisms Identified by
Whole-Genome Association Screening
To the Editor:
The 13 SNPs identified by Maraganore et al.1 as being
potentially associated with Parkinson disease (PD [MIM
168600]) represent some of the first fruit produced by
the whole-genome association screening era and are
clearly worthy of follow-up. To further explore these
exciting candidates, we typed each SNP in 538 patients
with idiopathic PD and in 516 control individuals from
the United Kingdom. Cases included 160 patients in-
volved in a community-based epidemiological study of
incident PD and 378 consecutive patients with prevalent
PD attending our research clinic. All cases met United
Kingdom Parkinson’s Disease Society Brain Bank criteria
for the diagnosis of PD. The mean age at disease onset
was 63 years (range 25–91 years); 2% of patients had
early-onset disease (40 years), and 14% of patients
reported a family history of one or more first-degree
relatives with parkinsonian symptoms or tremor. The
control group consisted of 146 spouses of patients with
PD and 370 blood donors. All individuals were white,
except for four patients and one spouse. All gave written
informed consent and a blood sample from which DNA
was extracted using standard methods. Genotyping was
performed using Taqman Assay-on-Demand (rs2245218)
and Assays-by-Design products on a 7900HT Sequence
Detection System (Applied Biosystems). Only samples
that typed successfully for at least one-third of markers
were included in the analysis (520 cases and 499 con-
trols). Genotyping success rates were all 97%, and no
marker showed evidence of deviation from Hardy-Wein-
berg equilibrium. Two pairs of SNPs (rs2313982 and
rs1509269; rs682705 and rs7520966) were found to be
in strong linkage disequilibrium ( , ),′ 2D p 1.0 r 1 0.69
which reduced the number of independent tests to 11.
Allele frequencies in cases and controls were compared
using the COCAPHASE program in the UNPHASED
package.2 Our study provides, on average, 85% power
(range 68%–96%) to detect the case-control differences
averaged over tier 1 and tier 2, as observed by Mara-
ganore et al.1
  
Table 1 
Genotype/Allele Frequencies of the Main 11 SNPs Nominated to Influence PD Susceptibility 
  
Ireland Norway United States 
dbSNP 
Accession 
Number Genotype Controls Cases Controls Cases Controls Cases 
rs2245218 AA:AG:GG 118:56:8 124:53:8 230:92:10 219:85:11 179:65:5 176:65:5 
rs7878232 TT:TG:GG 116:39:20 105:46:27 223:38:49 212:48:52 168:46:34 157:39:46 
rs1509269 CC:CT:TT 155:26:1 155:25:1 245:75:8 240:59:7 186:60:4 189:53:4 
rs11737074 GG:GA:AA 105:56:10 115:63:5 210:100:13 199:109:9 168:69:14 144:92:8 
rs7702187 TT:TA:AA 124:46:6 120:59:2 206:102:12 216:89:8 163:71:12 172:52:13 
rs10200894 CC:CG:GG 135:42:3 142:36:3 257:73:1 253:66:3 207:41:1 198:41:1 
rs2313982 CC:CT:TT 163:19:0 163:20:0 258:60:8 263:54:4 205:47:1 204:39:2 
rs17329669 AA:AG:GG 143:32:6 136:47:2 232:59:6 244:65:6 182:67:1 174:67:2 
rs7723605 TT:TC:CC 138:44:2 138:43:1 248:77:7 237:77:7 185:61:5 196:47:4 
rs16851009 CC:CT:TT 146:30:2 143:38:2 244:63:7 241:55:2 198:49:3 191:48:5 
ss46548856 GG:GC:CC 145:27:2 146:31:2 275:49:1 279:44:1 180:52:1 195:43:3 
rs682705 GG:GA:AA 86:72:16 107:55:12 162:104:26 170:127:27 132:91:23 121:107:12
rs7520966 CC:CT:TT 84:77:15 108:57:11 168:116:36 170:122:30 135:94:22 123:106:13
Am J Hum Genet. 2006 June; 78(6): 1084–1088.  
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bstract
The discovery of LRRK2 gene mutations in late-onset Parkinson’s disease (PD) has irrevocably established the role of genetics in the etiology of
D. The LRRK1 gene is the single homolog of LRRK2. A high degree of homology exists between LRRK1 and LRRK2, indicative of shared functions
nd/or pathways. One study has examined LRRK1 in familial parkinsonism by complete sequencing of the gene, reporting 4 novel non-synonymous
oding variants within the LRRK1 gene. One of these variants (ss65713826) was identified in a Norwegian proband. We investigated whether five
ommon polymorphisms or these recently identified coding changes within LRRK1 are associated with PD in the Norwegian population. Two rare
oding variants ss65713826 and ss65713830 were more frequent in patients than controls. However, their identification in healthy controls and
ack of co-segregation with disease suggests they may represent benign polymorphisms.
2007 Elsevier Ireland Ltd. All rights reserved.
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he etiology of Parkinson’s disease (PD, OMIM #168600)
emains unknown in the majority of patients. Although a number
f genes have been identified in familial forms of parkinsonism,
ittle progress has been made in elucidating the genetic com-
onent of late-onset PD [3]. The identification of pathogenic
ariants within the leucine-rich repeat kinase 2 gene (LRRK2;
MIM*609007), causing both familial parkinsonism and spo-
adic PD has reignited research interest. LRRK2 is located on
hromosome 12q12, contains 51 exons and encodes the 2527
mino acid protein Lrrk2 [3]. The Lrrk2 G2019S substitution is
n important cause of PD in Norway [1]. Recently, G2019S has
een identified in 30–37% of familial and 13–41% of sporadic
D patients in Ashkenazi Jews and North African Arabs [6].The identification of pathogenic mutations in presenilin 1 and
in Alzheimer’s disease is evidence that homologous proteins
an cause the same disease phenotype [8,10].LRRK2has a single
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oi:10.1016/j.neulet.2007.02.020omolog, LRRK1 (Chr 15q26.3, 156.5 kb, 33 Exons) [9]. There
s a high level of DNA/protein sequence and protein structure
omology suggesting that they may have similar functional-
ty [7]. Interestingly, Caenorhabditis elegans and Drosophila
elanogaster harbor only a single ortholog (Lrk-1) indicating
hat LRRK1 and LRRK2 in vertebrates have diverged from this
ommon ancestral gene [7]. Furthermore, phylogenetic analy-
es using the functional domains of the LRRK2 gene show that
RRK2 emerged from a gene duplication [9].
Our group recently identified four novel non-synonymous
oding variants within the LRRK1 gene through complete
equencing of all exons in 95 probands with autosomal dominant
arkinsonism (Table 1). These variants could not conclusively be
hown to segregate with disease in these families [11]. Herein,
e investigate five common single nucleotide polymorphisms
SNPs) and the four novel non-synonymous coding SNPs within
he LRRK1 gene to see if they are associated with susceptibility
o PD in the Norwegian population.All patients were examined and observed longitudinally by
movement disorder specialist (JOA) and diagnosed with PD
ccording to published criteria [5]. Patients with atypical symp-
oms or a known genetic cause of PD were excluded. Norwegian
300 K. Haugarvoll et al. / Neuroscience Letters 416 (2007) 299–301
Table 1
Allelic association between LRRK1 SNPs and PD
Marker Position Amino acid Alleles MAF in cases/controls χ2 (1 df) P-value* Permuted P-value
ss65713826 Exon 4 K203E A/G 0.011/0.002 4.548 0.03 0.17
rs7169323 Intron 6 – C/G 0.448/0.496 3.064 0.08 0.40
rs4965778 Exon 10 – A/G 0.413/0.393 0.576 0.45 0.97
rs11853661 Exon 15 T844T C/T 0.461/0.488 0.995 0.32 0.90
rs2925203 Intron16 – A/C 0.441/0.415 0.926 0.34 0.91
ss65713830 Exon 19 T967M C/T 0.005/0 3.173 0.07 0.36
ss65713838 Exon 31 P1796H C/A 0.006/0.006 0.006 0.94 1
ss65713839 Exon 31 R1850C C/T 0.012/0.008 0.718 0.40 0.95
rs2278953 3′ – C/T 0.334/0.31 0.904 0.34 0.92
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substitution has been shown to be a population specific risk fac-
tor for PD, we cannot rule out a role for LRRK1 variants in other
populations [4].
Fig. 1. The Norwegian pedigree F07 (Lrrk1 K203E). Squares represent malesesults from the matched case-control series. (*) Two tailed P-value for sing
ultiple testing was performed by permutations (n = 10,000).
amples consisted of 676 subjects (338 patients and 338 con-
rols) with mean age 70 ± 11 SD years (range 40–96 years),
ll originating from Central Norway. The male-to-female ratio
as 1.4:1, and the mean age at onset for patients was 58 ± 11
ears (range 25–88 years). About 15% of the PD patients in our
eries had a first degree relative also affected by PD. Each patient
as matched based on age (±4 years), gender and ethnicity to
n unrelated control without evidence of neurological disease.
hese and 249 further unmatched controls originated from the
ame geographical region in Central Norway. Participants pro-
ided informed consent and the ethical review boards at each
nstitution involved approved the study.
Genomic DNA was extracted from whole blood using a
tandard protocol. We selected five SNPs displaying moderate
nter-marker linkage disequilibrium (LD; r2 = 0.5–0.6) located
cross the LRRK1 locus (Available-by-Demand), and designed
our TaqMan Available-by-Design probes for the novel cod-
ng variants; Applied Biosystems, Inc. (Sequences available on
emand). Genotyping was performed on an ABI 7900 genetic
nalyzer and analyzed using SDS 2.2.2 software.
All SNPs were tested for Hardy–Weinberg equilibrium
HWE) in controls (P > 0.05). Individual allelic associations
etween PD and each SNP were investigated by χ2-square test
s implemented in Haploview software [2]. To correct for mul-
iple testing, we calculated empirical P-values by permutation
nalysis (n = 10000).
One novel non-synonymous LRRK1 variant ss65713826
607A > G, K203E) was more frequent in PD patients than
ontrols in our Norwegian series (Table 1). However, this dif-
erence was not significant after correction for multiple testing
P > 0.05). Interestingly, this variant was first identified in a Nor-
egian proband from a family displaying autosomal dominantly
nherited PD (Fig. 1). The variant did not co-segregate with dis-
ase in this family [11]. A further novel variant, ss65713830
2900C > T, T967M), first identified in a family of Eastern Euro-
ean descent without evidence of co-segregation with disease
as found in 3 patients, but no controls in our case-control study.
o association with PD was found for the other SNPs investi-
ated, including ss65713838 and ss65713839 identified in the
revious study (Table 1).
In order to obtain a better estimate of the frequency of the
wo novel variants (ss65713826 and ss65713830), we screened
a
g
w
(
frkers. MAF = Minor allele frequency. df = degrees of freedom. Correction for
further 249 Norwegian controls. ss65713826 (K203E) was
dentified in two controls aged 87 and 98 years, respectively.
s65713830 (T967M) was seen in one sixty years old control.
hese results, together with the lack of co-segregation with dis-
ase previously demonstrated for these two variants indicate that
hey most likely represent rare polymorphisms [11].
However, the reduced penetrance that has characterized
rrk2-associated disease demonstrates that caution should be
sed when classifying polymorphisms even if they are observed
n controls. Although LRRK1 is a candidate gene for PD, our
ata suggest that LRRK1 variants are not associated with PD in
he Norwegian population. Considering that the Lrrk2 G2385Rnd circles represent females, whereas a diamond is used to disguise the
ender/number of unaffected subjects. Deceased individuals are indicated
ith a diagonal line. The novel non-synonymous LRRK1 variant ss65713826
607A > G, K203E) was identified in the proband, indicated by (), but in no
urther family members, indicated by (–).
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[K. Haugarvoll et al. / Neurosc
LRRK2 has one single homolog, LRRK1 [7]. The functions
nd pathways of their gene products remain unknown, however
here is evidence supporting a kinase activity for both [7,12].
urthermore, there might be important functional interactions
etween Lrrk1 and Lrrk2, possibly implicating both proteins in
he pathology of PD. Further studies will hopefully advance
ur understanding of the mechanisms through which these
roteins act.
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